REYON Pharmaceutical Co., Ltd. (KRX:102460)

Market Cap	201.93B
Revenue (ttm)	148.30B
Net Income (ttm)	4.15B
Shares Out	18.34M
EPS (ttm)	226.00
PE Ratio	48.72
Forward PE	n/a
Dividend	150.00 (1.35%)
Ex-Dividend Date	Dec 27, 2024

Volume	16,173
Average Volume	29,554
Open	10,920
Previous Close	11,010
Day's Range	10,900 - 11,100
52-Week Range	9,830 - 18,650
Beta	0.90
RSI	44.18
Earnings Date	Mar 20, 2025

About REYON Pharmaceutical

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1955
• Employees: 448
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 102460

Financial Performance

In 2024, REYON Pharmaceutical's revenue was 148.30 billion, a decrease of -1.83% compared to the previous year's 151.07 billion. Earnings were 4.15 billion, an increase of 15.85%.